Wang Hui, Zhu Wan, Xu Cong, Su Wentao, Li Zhongyu
Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Shanghai General Hospital, Shanghai 200080, China.
Metabolism. 2025 Jan;162:156065. doi: 10.1016/j.metabol.2024.156065. Epub 2024 Nov 9.
Organoids-on-chips is an emerging innovative integration of stem cell-derived organoids with advanced organ-on-chip technology, providing a novel platform for the in vitro construction of biomimetic micro-physiological systems. The synergistic merger transcends the limitations of traditional drug screening and safety assessment methodologies, such as 2D cell cultures and animal models. In this review, we examine the prevailing challenges and prerequisites of preclinical models utilized for drug screening and safety evaluations. We highlighted the salient features and merits of organoids-on-chip, elucidating their capability to authentically replicate human physiology, thereby addressing contemporary impediments. We comprehensively overviewed the recent endeavors where organoids-on-chips have been harnessed for drug screening and safety assessment and delved into potential opportunities and challenges for evolving sophisticated, near-physiological organoids-on-chips. Based on current achievements, we further discuss how to enhance the practicality of organoids-on-chips and accelerate the translation from preclinical to clinical stages in healthcare and industry by utilizing multidisciplinary convergent innovation.
芯片上类器官是干细胞衍生类器官与先进的芯片上器官技术的一种新兴创新整合，为体外构建仿生微生理系统提供了一个新平台。这种协同融合超越了传统药物筛选和安全性评估方法（如二维细胞培养和动物模型）的局限性。在本综述中，我们研究了用于药物筛选和安全性评估的临床前模型当前面临的挑战和先决条件。我们强调了芯片上类器官的显著特征和优点，阐明了它们真实复制人体生理学的能力，从而解决了当代的障碍。我们全面概述了最近利用芯片上类器官进行药物筛选和安全性评估的努力，并深入探讨了发展复杂的、接近生理状态的芯片上类器官的潜在机遇和挑战。基于目前的成果，我们进一步讨论了如何提高芯片上类器官的实用性，并通过利用多学科融合创新加速其在医疗保健和工业领域从临床前到临床阶段的转化。
